Ann: Novogen update on Phase II Development Plans for GDC 0084, page-8

Wow that's great - its orally administered - way way easier than any of the body/peritoneal administered drugs... different class being GB.

And we are 3 months from second half, we have all the IND and 48KGs of the drug for the trial - times reported are proper at trial length 18 months, times reported are measured at 12 months for results reviews.

And the best part is some drugs get to go to market after phase 2 whilst phase three is conducted - this is a great announcement.

And even better - we will report progress along the way - comms are ramping up!

I'm very excited about this one - it's been a long wait for a good announcement.